Search This Blog

Tuesday, March 3, 2026

AnaptysBio to spin off biopharma business

 

 as First Tracks Biotherapeutics in Q2 2026, files Form 10

  • Reports Q4 2025 collaboration revenue of $108.2 million and net income of $49.6 million
  • Ended 2025 with $311.6 million in cash and investments on the balance sheet
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)